Goldman Sachs
OLMA icon

Goldman Sachs’s Olema Pharmaceuticals OLMA Stock Holding History

Goldman Sachs’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.6M Buy
1,045,589
+227,700
+28% +$5.07M ﹤0.01% 2683
2025
Q4 		$20.4M Buy
817,889
+14,008
+2% +$249K ﹤0.01% 2350
2025
Q3 		$7.87M Buy
803,881
+79,299
+11% +$476K ﹤0.01% 3203
2025
Q2 		$3.09M Sell
724,582
-16,747
-2% -$74.7K ﹤0.01% 3846
2025
Q1 		$2.79M Buy
741,329
+358,412
+94% +$1.8M ﹤0.01% 3883
2024
Q4 		$2.23M Sell
382,917
-79,430
-17% -$793K ﹤0.01% 4179
2024
Q3 		$5.52M Buy
462,347
+61,242
+15% +$783K ﹤0.01% 3253
2024
Q2 		$4.34M Sell
401,105
-35,926
-8% -$390K ﹤0.01% 3287
2024
Q1 		$4.95M Buy
437,031
+121,553
+39% +$1.57M ﹤0.01% 3099
2023
Q4 		$4.43M Buy
315,478
+221,543
+236% +$2.98M ﹤0.01% 3268
2023
Q3 		$1.16M Buy
93,935
+56,950
+154% +$580K ﹤0.01% 4166
2023
Q2 		$334K Sell
36,985
-3,910
-10% -$23.6K ﹤0.01% 4962
2023
Q1 		$142K Buy
40,895
+8,902
+28% +$36.3K ﹤0.01% 5398
2022
Q4 		$78.4K Sell
31,993
-157,016
-83% -$458K ﹤0.01% 5528
2022
Q3 		$522K Sell
189,009
-16,288
-8% -$69.1K ﹤0.01% 4941
2022
Q2 		$835K Sell
205,297
-240,651
-54% -$763K ﹤0.01% 4756
2022
Q1 		$1.9M Buy
445,948
+228,348
+105% +$1.26M ﹤0.01% 4311
2021
Q4 		$2.04M Buy
217,600
+66,981
+44% +$1.39M ﹤0.01% 4232
2021
Q3 		$4.15M Buy
150,619
+101,507
+207% +$2.74M ﹤0.01% 3510
2021
Q2 		$1.37M Buy
49,112
+28,011
+133% +$797K ﹤0.01% 4524
2021
Q1 		$700K Sell
21,101
-34,064
-62% -$1.46M ﹤0.01% 4881
2020
Q4 		$2.65M Buy
+55,165
New +$2.59M ﹤0.01% 3507

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Goldman Sachs's OLMA Position: Q1 2026 in Review

Goldman Sachs increased its Olema Pharmaceuticals (OLMA) stake by 28% in Q1 2026, buying an estimated $5.07M and bringing the position to 1,045,589 shares worth $15.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2683.

Goldman Sachs first reported a position in OLMA in Q4 2020 and has held it in 22 quarters since. The position peaked at $20.4M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Goldman Sachs held 1,045,589 shares of Olema Pharmaceuticals worth $15.6M as of Q1 2026.
  • Goldman Sachs bought 227,700 Olema Pharmaceuticals shares in Q1 2026, an estimated $5.07M.
  • Olema Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2683 holding.
  • Goldman Sachs first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Goldman Sachs's Olema Pharmaceuticals position peaked at $20.4M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.